# DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

> **NCT05368857** · PHASE1 · COMPLETED · sponsor: **Clinuvel (UK) Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers

## Interventions

- **DRUG:** Afamelanotide

## Key facts

- **NCT ID:** NCT05368857
- **Lead sponsor:** Clinuvel (UK) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368857, "DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05368857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*